Reading the tape
NASDAQ: GRCE
Grace Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$36.36M
52w High
$5.18
52w Low
$1.79
P/E
-5.82
Volume
6.41M
Outstanding Shares
15.47M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 2.17%FCF (TTM): 27.97%
What changed
The stock rose 2.17% over the last year. Free cash flow grew 27.97% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
CEOPrashant Kohli
SectorHealthcare
IndustryBiotechnology
Employees4
IPO dateFeb 7, 2012
Valuation
Forward P/E—
EV/EBITDA-0.33
Enterprise value$5.43M
Stock splits
Jul 10, 2023↓ Reverse
Every 6 shares became 1
Aug 31, 2021↓ Reverse
Every 8 shares became 1
Oct 15, 2015↓ Reverse
Every 10 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-14.36%▲31.00%vs FY2024
Analyst consensus
RatingBuy
Target price—
1
Buy
0
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jun 22, 2026
Q2 FY26 · EPS est -$0.24 · Revenue est $900K
View